# A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

Study · id `cardio:ct-nct07803679` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07803679](<https://clinicaltrials.gov/study/NCT07803679>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07803679

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 308 participants.

## Technical summary

Registry record NCT07803679. Randomized; single masking; primary purpose treatment. Start 2027-01-31 (anticipated); primary completion 2029-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 308 participants (planned count; ClinicalTrials.gov record NCT07803679, source copy `cardio:ctgov-nct07803679-2026-09-21`, retrieved 2026-10-26)
- Planned start: 2027-01-31 (anticipated) (ClinicalTrials.gov record NCT07803679, source copy `cardio:ctgov-nct07803679-2026-09-21`, retrieved 2026-10-26)
- Primary completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT07803679, source copy `cardio:ctgov-nct07803679-2026-09-21`, retrieved 2026-10-26)
- Completion: 2029-04-30 (anticipated) (ClinicalTrials.gov record NCT07803679, source copy `cardio:ctgov-nct07803679-2026-09-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07803679-2026-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
- Condition: Coronary Artery Disease
- Condition: Hypercholesterolemia
- Condition: Atheroma
- Condition: Atherosclerotic Plaque
- Intervention (Drug): Evolocumab
- Intervention (Drug): Routine Lipid Management
- Intervention (Device): Autoinjector
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: b1d86758a83065fcd81ba9c6ceede28d9aa80d488c2769227bfee78b543ba9ad
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
